Abstract
Event Abstract Back to Event Solutions for successful patient recruitment in early stage clinical trials Tea Kakabadze1 and Angela Bischoff2* 1 Arensia Exploratory Medicine, Clinical operations, Georgia 2 Arensia Exploratory Medicine, Clinical operations, Germany Background: In the today’s fast-changing world of drug development, fast patient recruitment is a compelling challenge in early stage clinical trials. The need for fast go/no-go decisions has triggered the early involvement of patients in exploratory trials where no treatment benefit is granted but a complex trial design is favoured. Consequently, patient recruitment became a speed limiting factor of drug development programs. Methods: The reporting clinical research organization has built a network of Phase I research units in Eastern Europe. Analysis of recruitment in selected trials in inflammatory, oncology and infectious diseases trials are presented, analysing obstacles and offering efficient solutions. Results: 1748 patients were enrolled 2011-2016 in 113 exploratory trials. Multi-fold patient rates compared to other sites were achieved. INSERT IMAGE 1 *ARENSIA, single site, specializing in early clinical development **average number of patients of active sites Discussion: High single centre patient recruitment rates were achieved using specific approaches in early stage clinical trials: geographic location, knowledge of the local health care systems and high motivation of the investigating teams. The creation of a tailor-made recruitment strategy alongside with post-trial treatment, recommendations for suitable trial designs, familiarity with the patient population and patient compensation are key factors for the speed of patient recruitment and retention. Keywords: early stage, recruitment, solution Conference: EUFEMED 2017, London, United Kingdom, 17 May - 19 May, 2017. Presentation Type: Poster Topic: EUFEMED 2017 CONFERENCE Citation: Kakabadze T and Bischoff A (2019). Solutions for successful patient recruitment in early stage clinical trials. Front. Pharmacol. Conference Abstract: EUFEMED 2017. doi: 10.3389/conf.fphar.2017.62.00013 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 29 Aug 2017; Published Online: 25 Jan 2019. * Correspondence: Dr. Angela Bischoff, Arensia Exploratory Medicine, Clinical operations, Dusseldorf, Germany, angela.bischoff@arensia-em.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Tea Kakabadze Angela Bischoff Google Tea Kakabadze Angela Bischoff Google Scholar Tea Kakabadze Angela Bischoff PubMed Tea Kakabadze Angela Bischoff Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.